FDA approves oral combination of Dacogen and Cedazuridine for patients with myelodysplastic syndromes

12/29/2020 By Dr. Dan Platt

Summary: The Food and Drug Administration (FDA) recently announced a new approved treatment option, Inqovi, for myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). It is an evolution from the existing treatment, decitabine (Dacogen), because it can be administered by month instead of IV.

Dr. Dan’s Takeaway: Inqovi has similar effectiveness and safety to IV decitabine (Dacogen), but it can be taken as a pill. It is therefore more convenient for patients, who will no longer have to go into the hospital for five consecutive days of IV Dacogen infusions every month.



Deskside with Dr. Dan

“One small way I am personally contributing to education is through sharing my take on academic and industry articles, using my medical background to boil down the jargon and pull out the benefits of the news for you.”

– Dan Platt, M.D.

Chief Medical Officer

About The Poster

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore the latest Hub posts


Top Tips for Dealing with Holiday Blues

Many people deal with the holiday blues, including several of our team members! The Gryt Health team came together to create this piece with some of our favorite tips and tricks for dealing with the Holiday Blues!

Tell Your Story

Irene’s Stomach Cancer Story

Gryt Health Community Member, Irene shares the start of her journey with Stomach Cancer.

Want Email Updates?

Get updates in your inbox when new content is posted on the website.

Find value in this post? Please share!

You are never alone

View our resources for those who are experiencing, have experienced, or are supporting someone who has experienced a medical diagnosis.